Close

BIO Releases Bioscience Economic Development Guide

The Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.

BIO 2015 International Convention Everyday Superhero Honorees Announced

The 2015 BIO International Convention announced the top Honorees in the association’s Everyday Superhero contest, recognizing biotech leaders in the patient, industry and academic communities whose accomplishments are helping those battling debilitating and chronic disease. Honorees were chosen from one of three categories: Patient/ Patient Group, Pharma/ Biotech and University Research Institutions.

New Research Shows Growing Industry-Academic Ties in Advancing New Medicines to Improve Patient Lives

BIO and Battelle's Technology Partnership Practice today released a report highlighting the growing and essential nature of industry-academic collaborations that bridge the gap between bioscience discoveries and the delivery of innovative products to improve medical outcomes in patients.

Council of State Bioscience Associations Announces New Board Leadership

...

BIO Elects New Chair, Officers, and Board Members

BIO is pleased to announce the election of Ron Cohen, MD, President & CEO, Acorda Therapeutics, as the new Chair of its Board of Directors for the 2015-2016 term. 

NASA Astronaut Scott Kelly to Give Live Interview from International Space Station at BIO 2015 Wednesday Keynote Luncheon

"We are thrilled to partner with NASA to make this exciting live interview from the International Space Station a reality for our event attendees,” said BIO International Convention President Scott Whitaker. “Advancing scientific research and progress is what drives the biotechnology industry - a drive shared by Commander Scott Kelly and NASA.”

BIO Opposes H.R. 9, The Innovation Act

BIO continues its continued opposition to The Innovation Act (H.R.9) as amended and reported by the House Judiciary Committee today.

BIO Releases Investment and Deal Making Study Showing Resurgence in Therapeutic Licensing

BIO released a new report - Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.

BIO Submits Comments on Draft PDUFA Meetings Guidance

The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the revised draft guidance for industry entitled “Formal Meetings Between the FDA and Sponsors or Applicants of Prescription Drug User Fee Act (PDUFA) Products.”

BIO Statement on Senate Judiciary Committee Passage of PATENT Act

BIO issued the following statement regarding the mark-up of The Protecting American Talent and Entrepreneurship (PATENT) Act